TAG:
cancer testing
Ascend Clinical Acquires PathCentral Lab Business
By Joseph Burns | From the Volume XIX No. 18 – December 31, 2012 Issue
CEO SUMMARY: Ascend Clinical and PathCentral see an opportunity to provide sophisticated services to community pathology groups. Ascend Clinical will expand the molecular diagnostic and gene sequencing business it is purchasing from PathCentral. PathCentral will concentrate on marketing i…
Sonic Healthcare, Bio-Reference Report Financial Performance
By Robert Michel | From the Volume XIX No. 13 – September 17, 2012 Issue
IN RECENT WEEKS, two of the nation’s larger public laboratory companies issued their earnings reports. In both cases, revenue growth was strong, a distinct difference from the recent financial performance of their two largest lab public company competitors. It was on August 21, 2012, when …
Grand River Hospital, Psyche Systems, Siemens Healthcare, Bio-Rad, Home Test Direct
By Robert Michel | From the Volume XIX No. 6 – April 23, 2012 Issue
HOSPITAL LAB CLOSED, STAFF EVACUATED AFTER LAB SPECIMEN SPILL IT’S NOT OFTEN THAT A HOSPITAL LABORATORY needs to be closed and decontaminated following a lab accident. Yet that is what happened on April 2 at 495-bed Grand River Hospital in Kitchner, Ontari…
July 25, 2011 “Intelligence: Late Breaking Lab News”
By Robert Michel | From the Volume XVIII No. 10 – July 25, 2011 Issue
In a play to expand its presence in cervical cancer testing, Roche Holdings announced an agreement to acquire mtm laboratories AG, based in Heidelberg, Germany. Roche will pay U.S. $180 million, plus another U.S. $85 million if performance milestones are achieved. mt…
May 23, 2011 “Intelligence: Late Breaking Lab News”
By Robert Michel | From the Volume XVIII No. 7 – May 23, 2011 Issue
The first sequencing of the whole human genome back in 2000 unleashed a tidal wave of research and development. Recently, Fast Company Magazine quantified the dollar impact of the Human Genome Project and now says it totals $800 billion! Their reporter communicates this so succinctly that TH…
August 23, 2010 “Intelligence: Late Breaking Lab News”
By Robert Michel | From the Volume XVII No. 12 – August 23, 2010 Issue
With the goal of developing biomarkers useful in diagnosing a variety of cancers, Pathwork Diagnostics, Inc., and Novartis AG announced a research partnership on July 30. It is an early example of a collaboration between a diagnostics company and a pharmaceutical com…
Serious Problems Plague Newfoundland Laboratory
By Robert Michel | From the Volume XVII No. 5 – March 29, 2010 Issue
CEO SUMMARY: Newfoundland’s St. John laboratory was rocked by revelations in February that its cyclosporine testing was flawed, exposing patients to the harmful affects from inappropriately high doses of the immunosuppressant drug. Within weeks of this news, the Chief of Laboratory Medi…
Two New Pathology Models Will Soon Be Tried in Dallas
By Robert Michel | From the Volume XVII No. 4 – March 8, 2010 Issue
CEO SUMMARY: There are notable aspects to how and why four unlikely partners are banding together to invest $40 million and create the nation’s newest reference and esoteric testing laboratory. It was the pathologists at Baylor University Hospital in Dallas, Texas, who originated the vi…
Baylor Pathologists Form Lab with US Oncology
By Robert Michel | From the Volume XVII No. 4 – March 8, 2010 Issue
CEO SUMMARY: In Dallas, Pathologists Bio-Medical Laboratories is part of a new laboratory partnership that includes Baylor Health Care System, Texas Oncology, and US Oncology. The four partners ponied up a total of $40 million in cash and debt to build a state-of-the art laboratory in a 1…
Beckman Coulter, Olympus, LabCorp, Anthem, WellPoint, Medtox, University of Toronto
By Robert Michel | From the Volume XVII No. 3 – February 15, 2010 Issue
BECKMAN COULTER REPORTS EARNINGS THAT INCLUDE OLYMPUS THERE WAS A BIG JUMP in fourth quarter revenue at Beckman Coulter Inc., of Brea, California, which increased by 22% over the previous year, to $989.6 million. This number included $120.2 million in reven…
CURRENT ISSUE

Volume XXXII, No. 6 – April 21, 2025
Now that a federal judge has vacated the FDA’s LDT rule, The Dark Report analyzes the judgement and notes the various steps the FDA could take in response. Also, lab testing at pharmacies is proving to be less successful than was once anticipated.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.
Topics
- Anatomic Pathology
- Clinical Chemistry
- Clinical Laboratory
- Clinical Laboratory Trends
- Digital Pathology
- Genetic Testing
- In Vitro Diagnostics
- IVD/Lab Informatics
- Lab Intelligence
- Lab Marketplace
- Lab Risk & Compliance
- Laboratory Automation
- Laboratory Billing
- Laboratory Compliance
- Laboratory Equipment
- Laboratory Information Systems
- Laboratory Management
- Lean Six Sigma
- Managed Care Contracts
- Molecular Diagnostics
- Pathology Trends
- People
- Uncategorized